Europe Neurodegenerative Disease Market

Market Overview

The worldwide neurodegenerative disease market size was estimated at USD 40,125 million in 2021, and it is predicted to reach USD 53,275 million by 2030, recording a CAGR of 3.2% during the forecast period (2022–2030).

In most cases, neurodegenerative disorders are characterised by gradual nerve cell degeneration that can occur in a variety of locations across the body. Loss of memory and cognitive control are potential outcomes of a number of conditions, including Alzheimer's disease, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), and amyotrophic lateral sclerosis (ALS).

Although there are very few diseases that can be cured, the pharmaceutical industry has developed a variety of treatments throughout the years that aim to alleviate the symptoms of neurodegenerative ailments.

Neurodegenerative disorders are a varied group of ailments defined by the gradual degradation of the function and structure of the central nervous system or peripheral nervous system. Neurodegenerative disorders, including Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Huntington's disease, have been rising globally. Thus, the growing burden of this condition is the key driver driving the market expansion, adding to it the expanding elderly population. According to NIH, nearly 1.2 million people in the United States will have Parkinson's disease by 2030. In the United States, it is the second most frequent neurodegenerative disorder.

Furthermore, according to Alzheimer's Disease International, more than 50 million adults with dementia globally in 2020. This number is anticipated to be more than double every two decades, reaching 82 million in 2030 and 152 million in 2050. Additionally, much of the increase will be in emerging countries. About 60% of persons with dementia reside in poor and middle-income nations, but by 2050, this will climb to 71%. The fastest rise in the senior population has happened in China, India, and South Asian and western Pacific countries. Thus, the growing burden of dementia is likely to enhance the market growth in the approaching years.

Europe: 16,165 million USD (2030 value); CAGR: 3.85%

Market Dynamics

Industry Drivers

The Europe neurodegenerative diseases market is gaining momentum as a result of an increased public awareness of the condition, an expanding elderly population, the possibility of the introduction of new drugs and products in the pipeline, and a relatively high rate of expansion in the therapeutic market. 

Dopaminergic neurons in the brain are specifically targeted by Parkinson's disease since it is a neurodegenerative sickness that progresses over time. Tremors, muscular stiffness, aberrant movement, difficulties walking, and balance issues are the most common symptoms of Parkinson's disease. Anxiety, sadness, and dementia are some of the secondary symptoms associated with this condition. Parkinson's disease is a degenerative neurological disorder that has no known cause and often strikes persons over the age of 50. Men, however, account for 50% of all cases of the condition in women. A diagnosis of Parkinson's disease is made in around 60,000 people in the United States each year, according to figures provided by the United States Parkinson Foundation. Worldwide, the condition is thought to impact between 70 and 10 million people. The high incidence and risk of this condition are one of the primary factors driving the expansion of the market for Parkinson's disease treatments in developed nations such as Europe.

The expansion of the market for Neurodegenerative treatment is anticipated to be driven by a greater understanding of neurological disease on the part of government and non-profit organisations, as well as increased spending on clinical research and development. Over the course of the forecast period, promising product channels will likely provide possible chances for the expansion of the firm.

Industry Restraints

On the other hand, it is anticipated that the expansion of Europe's Parkinson's disease treatment market will be hampered over the course of the projection year by the expiration of the patents on key products and by the adverse effects associated with therapeutic medicines.

The market for cutting-edge technologies is constrained by the accessibility of alternative treatment options.

Regional Analysis

The income generated in Europe in 2021 was estimated to be 11,500 million USD, making it the second-largest market. It is anticipated that by the year 2030, its value would have increased to USD 15,675 million, representing a CAGR of 3.5% for the time being analysed. Germany is home to a sizable number of worldwide enterprises engaged in the research and development of treatments for neurodegenerative diseases. Additionally, disease awareness and a rise in the number of medication releases by major pharmaceutical firms in the nation are likely to boost the market that has been researched. This is due to the growing incidence of these conditions.

In addition, it is anticipated that the number of individuals living with dementia would increase over the next several years, which would have a beneficial influence on the market. According to the Alzheimer Europe 2019 study, the number of persons living in Germany who were diagnosed with dementia in 2018 was around 1,585,166, and it is estimated that this figure would climb to 2,748,178 by the year 2050. In a similar vein, the percentage of the general population that is affected by dementia is projected to rise to 3.43% in 2050 from 1.91% in 2018.

Segmental Analysis

The Europe neurodegenerative diseases market is segmented according to the kind of indication, the type of medicine, and the geography.

Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and other indication types make up the Europe neurodegenerative diseases market. Various indication types include other neurodegenerative diseases. Multiple sclerosis was the most lucrative sector of the market in 2021, bringing in a total of USD 25,680 million in sales. It is anticipated that it would reach USD 29,360 million by the year 2030, recording a CAGR of 1.5% over the duration of the prediction.

The number of people living with multiple sclerosis has risen in every region of the world. It is anticipated that the overwhelming majority of multiple sclerosis cases throughout the world will drive market growth. In addition, another key growth aspect is the growing interest of businesses in the items that are in the pipeline, as well as the comprehensive product approvals. For example, in October 2019, the United States Food and Drug Administration granted approval for the treatment of relapsing forms of multiple sclerosis (MS) to Vumerity (diroximel fumarate), an oral fumarate formulation of the drug. This approval covers clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Recent Developments

UCB made the announcement in July 2021 that they had entered into a worldwide licencing deal with Roche and Genentech to collaborate on the development and commercialization of UCB0107 for Alzheimer's Disease.

In January of 2020, Novartis made the announcement that it will be acquiring Cadent Therapeutics to broaden its neuroscience portfolio. Patients diagnosed with mild-to-moderate Alzheimer's disease can now be treated with Belsomra for insomnia, since the medication has received approval from the Food and Drug Administration in the United States. Merck made the announcement. Portfolio in the field of schizophrenia as well as other movement disorders.